Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:02:52.300Z.
Calculation as of: 2026-10-06T18:02:52.300Z.
Quote observation: 2026-10-06T17:58:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc2e94c8beea8e322b310e9b25a1b89028fd55b2fc6a2790cf1d230843e32158
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$36.90M
PS Ratio
N/A
TTM Avg
65299.11
3Y Avg
21900.20
5Y Avg
13187.22
Market Cap
$35.48M
PS Ratio
3.02
TTM Avg
7.06
3Y Avg
18.39
5Y Avg
15.88
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $37.75M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $37.67M | 1.82 | 2.43 | 1.99 | 2.26 |
| Edesa Biotech, Inc. (EDSA)vs › | $36.90M | N/A | 65299.11 | 21900.20 | 13187.22 |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.88M | 0.44 | 0.32 | 0.77 | 1.11 |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.15M | 2.89 | 2.35 | 2.86 | 2.86 |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | 1.29 | 6.96 | 23.74 | 23.74 |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.57M | 0.12 | 0.22 | 0.47 | 1.32 |
| EUDA Health Holdings Limited (EUDA)vs › | $35.48M | 3.02 | 7.06 | 18.39 | 15.88 |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.35M | N/A | N/A | N/A | N/A |
Half-year reporter: no trailing two-half-year basis, because the half-year figures cannot be checked against the annual report: the newest completed fiscal year's annual revenue and net income are both below 25 million, too small to compare.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
